Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein Ilb/Illa inhibitors during rescue angioplasty

被引:16
作者
Boccalandro, F
Assali, A
Fujise, K
Smalling, RW
Sdringola, S
机构
[1] Univ Texas, Sch Med, Div Cardiol, Houston, TX 77030 USA
[2] Mem Hermann Hos, Houston, TX USA
[3] Rabin Med Ctr, Dept Cardiol, Petah Tiqwa, Israel
关键词
rescue angioplasty; vascular closure devices; glycoprotein Ilb/Illa inhibitors; manual compression;
D O I
10.1002/ccd.20171
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to evaluate the effectiveness of two different closure devices in patients undergoing rescue percutaneous coronary intervention (PCI) using IIb/IIIa inhibitors and to compare it with patients undergoing elective PCI. One hundred sixty-two patients undergoing rescue PCI treated with IIb/IIIa inhibitors underwent vascular access site closure (6 Fr Perclose, n = 92, or 6 Fr Angioseal, n = 70). Vascular complications were compared with a sex- and age-matched group (n = 100) of patients undergoing manual compression after sheath removal and a similar group of patients undergoing elective PCI (n = 196). The incidence of access site complications was not significantly different between the three groups undergoing rescue PCI and was not higher than in patient receiving GP IIb/IIIa inhibitors without fibrinolysis (RR = 0.95; 95% CI = 0.88-1.01). In patients undergoing rescue PCI and receiving IIb/IIIa inhibitors, closure devices allow early sheath removal and are associated with similar outcomes compared with manual compression and elective PCI regardless of the type of closure device used. Catheter Cardiovasc Interv 2004,63.284-289. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:284 / 289
页数:6
相关论文
共 34 条
[1]   BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].
AGUIRRE, FV ;
TOPOL, EJ ;
FERGUSON, JJ ;
ANDERSON, K ;
BLANKENSHIP, JC ;
HEUSER, RR ;
SIGMON, K ;
TAYLOR, M ;
GOTTLIEB, R ;
HANOVICH, G ;
ROSENBERG, M ;
DONOHUE, TJ ;
WEISMAN, HF ;
CALIFF, RM .
CIRCULATION, 1995, 91 (12) :2882-2890
[2]   Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty [J].
Antoniucci, D ;
Valenti, R ;
Migliorini, A ;
Moschi, G ;
Trapani, M ;
Buonamici, P ;
Cerisano, G ;
Bolognese, L ;
Santoro, GM .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (11) :1248-1252
[3]   Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization [J].
Applegate, RJ ;
Grabarczyk, MA ;
Little, WC ;
Craven, T ;
Walkup, M ;
Kahl, FR ;
Braden, GA ;
Rankin, KM ;
Kutcher, MA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (01) :78-83
[4]   Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices [J].
Assali, AR ;
Sdringola, S ;
Moustapha, A ;
Ghani, M ;
Salloum, J ;
Schroth, G ;
Fujise, K ;
Anderson, HV ;
Smalling, RW ;
Rosales, OR .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (01) :1-5
[5]   Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials [J].
Blankenship, JC ;
Balog, C ;
Sapp, SK ;
Califf, RM ;
Lincoff, AM ;
Tcheng, JE ;
Topol, EJ .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 57 (04) :476-483
[6]   Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study [J].
Bonnefoy, E ;
Lapostolle, F ;
Leizorovicz, A ;
Steg, G ;
McFadden, EP ;
Dubien, PY ;
Cattan, S ;
Boullenger, E ;
Machecourt, J ;
Lacroute, JM ;
Cassagnes, J ;
Dissait, F ;
Touboul, P .
LANCET, 2002, 360 (9336) :825-829
[7]   Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction [J].
Brener, SJ ;
Barr, LA ;
Burchenal, JEB ;
Katz, S ;
George, BS ;
Jones, AA ;
Cohen, ED ;
Gainey, PC ;
White, HJ ;
Cheek, HB ;
Moses, JW ;
Moliterno, DJ ;
Effron, MB ;
Topol, EJ .
CIRCULATION, 1998, 98 (08) :734-741
[8]   Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction - The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial [J].
Brener, SJ ;
Zeymer, U ;
Adgey, AAJ ;
Vrobel, TR ;
Ellis, SG ;
Neuhaus, KL ;
Juran, N ;
Ivanc, TB ;
Ohman, EM ;
Strony, J ;
Kitt, M ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (03) :377-386
[9]  
Carey D, 2001, CATHETER CARDIO INTE, V52, P3, DOI 10.1002/1522-726X(200101)52:1<3::AID-CCD1002>3.0.CO
[10]  
2-G